Literature DB >> 33586651

A survey of psoriasis patients on biologics during COVID-19: a high-epidemic area experience - Franche Comté, France.

Irène Gallais-Serezal1, Eve Puzenat2, Joséphine Moreau3, Flora Dresco2, Fabien Pelletier1, Charlée Nardin1, François Aubin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33586651      PMCID： PMC8120764          DOI： 10.1684/ejd.2020.3960

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN： 1167-1122            Impact factor:   3.328


× No keyword cloud information.
  9 in total

1.  A survey of psoriasis patients on biologics during COVID-19: a single centre experience.

Authors:  Martina Burlando; Luca Carmisciano; Emanuele Cozzani; Aurora Parodi
Journal:  J Dermatolog Treat       Date:  2020-05-25       Impact factor: 3.359

2.  Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.

Authors:  Giovanni Damiani; Alessia Pacifico; Nicola L Bragazzi; Piergiorgio Malagoli
Journal:  Dermatol Ther       Date:  2020-05-19       Impact factor: 2.851

3.  COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy.

Authors:  Andrea Carugno; Daniele Mario Gambini; Francesca Raponi; Pamela Vezzoli; Andrea Gustavo C Locatelli; Marco Di Mercurio; Elisa Robustelli Test; Paolo Sena
Journal:  J Am Acad Dermatol       Date:  2020-05-06       Impact factor: 11.527

4.  Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.

Authors:  A-C Fougerousse; M Perrussel; P-A Bécherel; E Begon; V Pallure; I Zaraa; G Chaby; J Parier; M Kemula; L Mery-Bossard; C Poreaux; C Taieb; F Maccari; Z Reguiai
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-07-09       Impact factor: 9.228

5.  The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.

Authors:  P Gisondi; P Facheris; P Dapavo; S Piaserico; A Conti; L Naldi; S Cazzaniga; P Malagoli; A Costanzo
Journal:  Br J Dermatol       Date:  2020-05-28       Impact factor: 11.113

6.  COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.

Authors:  Claudio Conforti; Roberta Giuffrida; Caterina Dianzani; Nicola Di Meo; Iris Zalaudek
Journal:  Dermatol Ther       Date:  2020-03-22       Impact factor: 2.851

7.  Should biologics for psoriasis be interrupted in the era of COVID-19?

Authors:  Mark Lebwohl; Ryan Rivera-Oyola; Dedee F Murrell
Journal:  J Am Acad Dermatol       Date:  2020-03-19       Impact factor: 11.527

8.  Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.

Authors:  Nicholas D Brownstone; Quinn G Thibodeaux; Vidhatha D Reddy; Bridget A Myers; Stephanie Y Chan; Tina Bhutani; Wilson Liao
Journal:  Dermatol Ther (Heidelb)       Date:  2020-04-16

9.  Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.

Authors:  Satveer K Mahil; Nick Dand; Kayleigh J Mason; Zenas Z N Yiu; Teresa Tsakok; Freya Meynell; Bola Coker; Helen McAteer; Lucy Moorhead; Teena Mackenzie; Maria Teresa Rossi; Raquel Rivera; Emmanuel Mahe; Andrea Carugno; Michela Magnano; Giulia Rech; Esther A Balogh; Steven R Feldman; Claudia De La Cruz; Siew Eng Choon; Luigi Naldi; Jo Lambert; Phyllis Spuls; Denis Jullien; Hervé Bachelez; Devon E McMahon; Esther E Freeman; Paolo Gisondi; Luis Puig; Richard B Warren; Paola Di Meglio; Sinéad M Langan; Francesca Capon; Christopher E M Griffiths; Jonathan N Barker; Catherine H Smith
Journal:  J Allergy Clin Immunol       Date:  2020-10-16       Impact factor: 10.793
  9 in total
  1 in total

Review 1.  Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.

Authors:  Elia Rosi; Maria Thais Fastame; Antonella Di Cesare; Gianmarco Silvi; Nicola Pimpinelli; Francesca Prignano
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.